Importantly, while our findings suggest LKB1 as a prognostic marker, we did not provide mechanistic validation through functional assays with SCLC cells, such as gene knockdown models, cytokine profiling, or immune response assays, as these were beyond the scope of our study. The gene discussed is STK11; the disease is small cell lung carcinoma.